Digital Therapeutics Revolutionize U.S. Healthcare in 2025
United States, Monday, 27 October 2025.
In 2025, digital therapeutics and AI advance U.S. healthcare with tools like CADx systems and wearable tech, enhancing diagnostic accuracy and patient care. These shifts promote preventive care models.
Digital Health Market Growth
The digital health market in the United States is experiencing unprecedented growth, valued between $288-313 billion in 2024 and projected to reach $946 billion by 2030. This growth, at a compound annual growth rate (CAGR) of 22.2%, is driven by factors such as increased smartphone penetration and the rising burden of chronic diseases. North America currently commands a substantial market share, accounting for 37-43% of the global digital health market [1].
Remote Patient Monitoring (RPM) and Its Impact
Remote Patient Monitoring (RPM) is a cornerstone of this digital transformation, allowing for the transmission of health data from remote locations to healthcare providers. In the United States, the RPM market reached between $12.76-27.72 billion in 2024 and is projected to grow to a range of $32-57 billion by 2030-2032. Notably, 46.3% of US hospitals now offer RPM services, which have significantly reduced hospital readmissions by 76% and hypertensive hospitalizations by 50% [1].
Advancements in Digital Therapeutics
Digital therapeutics (DTx) are pivotal in redefining healthcare delivery by providing personalized, accessible, and scalable interventions, particularly for chronic conditions and mental health. The global DTx market was valued at $7.67 billion in 2024 and is expected to grow to $32.5 billion by 2030. Despite its potential, the industry faces challenges such as regulatory hurdles, with only 20 DTx approved by the FDA in 2024 [1].
The Role of AI in Healthcare Transformation
Artificial intelligence (AI) is at the forefront of healthcare innovation, supporting health professionals and enhancing patient care. AI technologies, such as Computer-Aided Diagnosis (CADx) systems, are improving diagnostic accuracy with sensitivities up to 98%. The US CADx market was valued at $742-892 million between 2021 and 2025 and is projected to reach $1,377-2,260 million by 2030-2032 [1][2].
Addressing Accessibility with Digital Therapeutics
At the CHEST 2025 conference, a digital therapeutic app was presented to enhance access to behavioral cough suppression therapy for patients with refractory chronic cough. This app integrates elements of BCST, demonstrating a 40% reduction in cough frequency and significant quality of life improvements. It exemplifies how digital therapeutics can improve accessibility and efficacy of treatments for chronic conditions [2].